To construct the tissue engineering urethral material that is closest to the normal urethral structure in the true sense in vitro. Abdominal ADSC from a 2-month-old New Zealand white rabbit was extracted and directly compounded with non-woven polyglycolic acid (PGA) (control
group) to induce the differentiation of myoblasts and epithelial-like cells in vitro and shaped into urethral structure lumen Observation group); After Gd chelating protein nano-labeling and VEGF-loaded sustained release, the rabbit model of a long urethral defect was replanted and
cultured for 4 weeks, 8 weeks and 12 weeks, respectively. There was no difference in urinary tract patency rate, urinary tract infection, and renal dysfunction rate between the two groups (P > 0.05). The urine flow rate in the observation group was significantly higher than that
in the control group, and the residual volume decreased (P < 0.05). The blood vessel density and CD31 percentage in the observation group increased (P < 0.05). Compared with the conventional ADSC directly in contact with the composite material to construct the urethra,
in vitro induction of ADSC to myoblasts and epithelial-like cells respectively, and then use the cell membrane technology to build a tissue engineering urethral material that is closest to the normal urethral structure in the true sense, and loaded with VEGF Loop release technology
can significantly improve urodynamic functions, optimize tissue engineering urethral structure and vascularization, and is expected to become a new technology for constructing new tissue engineering urethral materials.